APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market Outlook and Growth Opportunities 2026

2 January 2026201 pages

Choose your research edition.

Industry ResearchVaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market include CNADC, Guangdong Yongshun Biological Pharmaceutical Co Ltd, Tiankang, Tianjin Ruipu Biological Technology Co., Ltd., Qilu Animal Health, Plec Bioengineering Co., Ltd., Jinyu Bio-Technology, Sinopharm and Guangdong Wens Dahuanong Biotechnology Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market size, projected growth trends, production technologies, key applications, and end-use industries.

Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Segment by Company

CNADC

Guangdong Yongshun Biological Pharmaceutical Co Ltd

Tiankang

Tianjin Ruipu Biological Technology Co., Ltd.

Qilu Animal Health

Plec Bioengineering Co., Ltd.

Jinyu Bio-Technology

Sinopharm

Guangdong Wens Dahuanong Biotechnology Co., Ltd.

Chengdu Tianbang Biological Products Co., Ltd.

Boehringer-Ingelheim

Zoetis

Phibro Animal Health

MSD Animal Health

Komipharm

Ceva

CAVAC

Bioveta

Agrovet

Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Segment by Type

Live Vaccine

Inactivated Vaccine

Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Segment by Application

Government Tender

Marketing

Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) significant trends, drivers, influence factors in global and regions.

6. To analyze Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) industry.

Chapter 3: Detailed analysis of Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Trends Table 2. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Drivers Table 3. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Opportunities and Challenges Table 4. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Restraints Table 5. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue Share by Company (2021-2026) Table 7. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume Share by Company (2021-2026) Table 9. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Key Company Manufacturing Base & Headquarters Table 12. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Company, Product Type & Application Table 13. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Live Vaccine Table 18. Significant Companies of Inactivated Vaccine Table 19. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume Share by Type (2021-2026) Table 23. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume Share by Type (2027-2032) Table 24. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type (2021-2026) Table 28. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Government Tender Table 30. Significant Companies of Marketing Table 31. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume Share by Application (2021-2026) Table 35. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume Share by Application (2027-2032) Table 36. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application (2021-2026) Table 40. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application (2027-2032) Table 41. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Region (2021-2026) & (K Units) Table 43. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Market Share by Region (2021-2026) Table 44. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Region (2027-2032) & (K Units) Table 45. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Market Share by Region (2027-2032) Table 46. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Region (2021-2026) Table 49. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Region (2027-2032) Table 51. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Country (2021-2026) & (K Units) Table 56. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Market Share by Country (2021-2026) Table 57. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Country (2027-2032) & (K Units) Table 58. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Market Share by Country (2027-2032) Table 59. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Market Share by Country (2021-2026) Table 61. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Market Share by Country (2027-2032) Table 63. CNADC Company Information Table 64. CNADC Business Overview Table 65. CNADC Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. CNADC Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 67. CNADC Recent Development Table 68. Guangdong Yongshun Biological Pharmaceutical Co Ltd Company Information Table 69. Guangdong Yongshun Biological Pharmaceutical Co Ltd Business Overview Table 70. Guangdong Yongshun Biological Pharmaceutical Co Ltd Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Guangdong Yongshun Biological Pharmaceutical Co Ltd Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 72. Guangdong Yongshun Biological Pharmaceutical Co Ltd Recent Development Table 73. Tiankang Company Information Table 74. Tiankang Business Overview Table 75. Tiankang Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Tiankang Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 77. Tiankang Recent Development Table 78. Tianjin Ruipu Biological Technology Co., Ltd. Company Information Table 79. Tianjin Ruipu Biological Technology Co., Ltd. Business Overview Table 80. Tianjin Ruipu Biological Technology Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Tianjin Ruipu Biological Technology Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 82. Tianjin Ruipu Biological Technology Co., Ltd. Recent Development Table 83. Qilu Animal Health Company Information Table 84. Qilu Animal Health Business Overview Table 85. Qilu Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Qilu Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 87. Qilu Animal Health Recent Development Table 88. Plec Bioengineering Co., Ltd. Company Information Table 89. Plec Bioengineering Co., Ltd. Business Overview Table 90. Plec Bioengineering Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Plec Bioengineering Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 92. Plec Bioengineering Co., Ltd. Recent Development Table 93. Jinyu Bio-Technology Company Information Table 94. Jinyu Bio-Technology Business Overview Table 95. Jinyu Bio-Technology Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Jinyu Bio-Technology Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 97. Jinyu Bio-Technology Recent Development Table 98. Sinopharm Company Information Table 99. Sinopharm Business Overview Table 100. Sinopharm Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Sinopharm Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 102. Sinopharm Recent Development Table 103. Guangdong Wens Dahuanong Biotechnology Co., Ltd. Company Information Table 104. Guangdong Wens Dahuanong Biotechnology Co., Ltd. Business Overview Table 105. Guangdong Wens Dahuanong Biotechnology Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Guangdong Wens Dahuanong Biotechnology Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 107. Guangdong Wens Dahuanong Biotechnology Co., Ltd. Recent Development Table 108. Chengdu Tianbang Biological Products Co., Ltd. Company Information Table 109. Chengdu Tianbang Biological Products Co., Ltd. Business Overview Table 110. Chengdu Tianbang Biological Products Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Chengdu Tianbang Biological Products Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 112. Chengdu Tianbang Biological Products Co., Ltd. Recent Development Table 113. Boehringer-Ingelheim Company Information Table 114. Boehringer-Ingelheim Business Overview Table 115. Boehringer-Ingelheim Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Boehringer-Ingelheim Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 117. Boehringer-Ingelheim Recent Development Table 118. Zoetis Company Information Table 119. Zoetis Business Overview Table 120. Zoetis Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Zoetis Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 122. Zoetis Recent Development Table 123. Phibro Animal Health Company Information Table 124. Phibro Animal Health Business Overview Table 125. Phibro Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Phibro Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 127. Phibro Animal Health Recent Development Table 128. MSD Animal Health Company Information Table 129. MSD Animal Health Business Overview Table 130. MSD Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. MSD Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 132. MSD Animal Health Recent Development Table 133. Komipharm Company Information Table 134. Komipharm Business Overview Table 135. Komipharm Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Komipharm Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 137. Komipharm Recent Development Table 138. Ceva Company Information Table 139. Ceva Business Overview Table 140. Ceva Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Ceva Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 142. Ceva Recent Development Table 143. CAVAC Company Information Table 144. CAVAC Business Overview Table 145. CAVAC Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. CAVAC Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 147. CAVAC Recent Development Table 148. Bioveta Company Information Table 149. Bioveta Business Overview Table 150. Bioveta Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Bioveta Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 152. Bioveta Recent Development Table 153. Agrovet Company Information Table 154. Agrovet Business Overview Table 155. Agrovet Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 156. Agrovet Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio Table 157. Agrovet Recent Development Table 158. Key Raw Materials Table 159. Raw Materials Key Suppliers Table 160. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Distributors List Table 161. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Customers List Table 162. Research Programs/Design for This Report Table 163. Authors List of This Report Table 164. Secondary Sources Table 165. Primary Sources List of Figures Figure 1. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Image Figure 2. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales (2021-2032) & (K Units) Figure 5. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Live Vaccine Image Figure 10. Inactivated Vaccine Image Figure 11. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume Share by Type (2021-2032) Figure 14. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type (2021-2032) Figure 17. Government Tender Image Figure 18. Marketing Image Figure 19. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume Share by Application (2021-2032) Figure 22. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application (2021-2032) Figure 25. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value (2021-2032) & (US$ Million) Figure 30. North America Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value (2021-2032) & (US$ Million) Figure 36. South America Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Ra

Scope & coverage.

Types
  • Live Vaccine
  • Inactivated Vaccine
Applications
  • Government Tender
  • Marketing
Companies covered
  • CNADC
  • Guangdong Yongshun Biological Pharmaceutical Co Ltd
  • Tiankang
  • Tianjin Ruipu Biological Technology Co., Ltd.
  • Qilu Animal Health
  • Plec Bioengineering Co., Ltd.
  • Jinyu Bio-Technology
  • Sinopharm
  • Guangdong Wens Dahuanong Biotechnology Co., Ltd.
  • Chengdu Tianbang Biological Products Co., Ltd.
  • Boehringer-Ingelheim
  • Zoetis
  • Phibro Animal Health
  • MSD Animal Health
  • Komipharm
  • Ceva
  • CAVAC
  • Bioveta
  • Agrovet

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value (2021-2032)
  4. 1.2.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume (2021-2032)
  5. 1.2.3 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market Dynamics
  1. 2.1 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Trends
  2. 2.2 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Drivers
  3. 2.3 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Opportunities and Challenges
  4. 2.4 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Restraints
3 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market by Company
  1. 3.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Company Revenue Ranking in 2025
  2. 3.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Revenue by Company (2021-2026)
  3. 3.3 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume by Company (2021-2026)
  4. 3.4 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Average Price by Company (2021-2026)
  5. 3.5 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Company Ranking (2024-2026)
  6. 3.6 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Company Manufacturing Base and Headquarters
  7. 3.7 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Company Product Type and Application
  8. 3.8 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market by Type
  1. 4.1 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Type Introduction
  2. 4.1.1 Live Vaccine
  3. 4.1.2 Inactivated Vaccine
  4. 4.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume by Type
  5. 4.2.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Type
  9. 4.3.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Type (2021-2032)
  11. 4.3.3 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type (2021-2032)
5 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market by Application
  1. 5.1 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Application Introduction
  2. 5.1.1 Government Tender
  3. 5.1.2 Marketing
  4. 5.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume by Application
  5. 5.2.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Application
  9. 5.3.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Application (2021-2032)
  11. 5.3.3 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application (2021-2032)
6 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Regional Sales and Value Analysis
  1. 6.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Region (2021-2032)
  3. 6.2.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Region: 2021-2026
  4. 6.2.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Region (2027-2032)
  5. 6.3 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Region (2027-2032)
  9. 6.5 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value (2021-2032)
  12. 6.6.2 North America Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value (2021-2032)
  15. 6.7.2 Europe Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value (2021-2032)
  21. 6.9.2 South America Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Country, 2025 VS 2032
7 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Country-level Sales and Value Analysis
  1. 7.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Country (2021-2032)
  4. 7.3.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Country (2021-2026)
  5. 7.3.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales by Country (2027-2032)
  6. 7.4 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CNADC
  2. 8.1.1 CNADC Company Information
  3. 8.1.2 CNADC Business Overview
  4. 8.1.3 CNADC Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 CNADC Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  6. 8.1.5 CNADC Recent Developments
  7. 8.2 Guangdong Yongshun Biological Pharmaceutical Co Ltd
  8. 8.2.1 Guangdong Yongshun Biological Pharmaceutical Co Ltd Company Information
  9. 8.2.2 Guangdong Yongshun Biological Pharmaceutical Co Ltd Business Overview
  10. 8.2.3 Guangdong Yongshun Biological Pharmaceutical Co Ltd Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Guangdong Yongshun Biological Pharmaceutical Co Ltd Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  12. 8.2.5 Guangdong Yongshun Biological Pharmaceutical Co Ltd Recent Developments
  13. 8.3 Tiankang
  14. 8.3.1 Tiankang Company Information
  15. 8.3.2 Tiankang Business Overview
  16. 8.3.3 Tiankang Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Tiankang Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  18. 8.3.5 Tiankang Recent Developments
  19. 8.4 Tianjin Ruipu Biological Technology Co., Ltd.
  20. 8.4.1 Tianjin Ruipu Biological Technology Co., Ltd. Company Information
  21. 8.4.2 Tianjin Ruipu Biological Technology Co., Ltd. Business Overview
  22. 8.4.3 Tianjin Ruipu Biological Technology Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Tianjin Ruipu Biological Technology Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  24. 8.4.5 Tianjin Ruipu Biological Technology Co., Ltd. Recent Developments
  25. 8.5 Qilu Animal Health
  26. 8.5.1 Qilu Animal Health Company Information
  27. 8.5.2 Qilu Animal Health Business Overview
  28. 8.5.3 Qilu Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Qilu Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  30. 8.5.5 Qilu Animal Health Recent Developments
  31. 8.6 Plec Bioengineering Co., Ltd.
  32. 8.6.1 Plec Bioengineering Co., Ltd. Company Information
  33. 8.6.2 Plec Bioengineering Co., Ltd. Business Overview
  34. 8.6.3 Plec Bioengineering Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Plec Bioengineering Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  36. 8.6.5 Plec Bioengineering Co., Ltd. Recent Developments
  37. 8.7 Jinyu Bio-Technology
  38. 8.7.1 Jinyu Bio-Technology Company Information
  39. 8.7.2 Jinyu Bio-Technology Business Overview
  40. 8.7.3 Jinyu Bio-Technology Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Jinyu Bio-Technology Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  42. 8.7.5 Jinyu Bio-Technology Recent Developments
  43. 8.8 Sinopharm
  44. 8.8.1 Sinopharm Company Information
  45. 8.8.2 Sinopharm Business Overview
  46. 8.8.3 Sinopharm Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sinopharm Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  48. 8.8.5 Sinopharm Recent Developments
  49. 8.9 Guangdong Wens Dahuanong Biotechnology Co., Ltd.
  50. 8.9.1 Guangdong Wens Dahuanong Biotechnology Co., Ltd. Company Information
  51. 8.9.2 Guangdong Wens Dahuanong Biotechnology Co., Ltd. Business Overview
  52. 8.9.3 Guangdong Wens Dahuanong Biotechnology Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Guangdong Wens Dahuanong Biotechnology Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  54. 8.9.5 Guangdong Wens Dahuanong Biotechnology Co., Ltd. Recent Developments
  55. 8.10 Chengdu Tianbang Biological Products Co., Ltd.
  56. 8.10.1 Chengdu Tianbang Biological Products Co., Ltd. Company Information
  57. 8.10.2 Chengdu Tianbang Biological Products Co., Ltd. Business Overview
  58. 8.10.3 Chengdu Tianbang Biological Products Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Chengdu Tianbang Biological Products Co., Ltd. Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  60. 8.10.5 Chengdu Tianbang Biological Products Co., Ltd. Recent Developments
  61. 8.11 Boehringer-Ingelheim
  62. 8.11.1 Boehringer-Ingelheim Company Information
  63. 8.11.2 Boehringer-Ingelheim Business Overview
  64. 8.11.3 Boehringer-Ingelheim Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Boehringer-Ingelheim Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  66. 8.11.5 Boehringer-Ingelheim Recent Developments
  67. 8.12 Zoetis
  68. 8.12.1 Zoetis Company Information
  69. 8.12.2 Zoetis Business Overview
  70. 8.12.3 Zoetis Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Zoetis Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  72. 8.12.5 Zoetis Recent Developments
  73. 8.13 Phibro Animal Health
  74. 8.13.1 Phibro Animal Health Company Information
  75. 8.13.2 Phibro Animal Health Business Overview
  76. 8.13.3 Phibro Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Phibro Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  78. 8.13.5 Phibro Animal Health Recent Developments
  79. 8.14 MSD Animal Health
  80. 8.14.1 MSD Animal Health Company Information
  81. 8.14.2 MSD Animal Health Business Overview
  82. 8.14.3 MSD Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 MSD Animal Health Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  84. 8.14.5 MSD Animal Health Recent Developments
  85. 8.15 Komipharm
  86. 8.15.1 Komipharm Company Information
  87. 8.15.2 Komipharm Business Overview
  88. 8.15.3 Komipharm Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Komipharm Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  90. 8.15.5 Komipharm Recent Developments
  91. 8.16 Ceva
  92. 8.16.1 Ceva Company Information
  93. 8.16.2 Ceva Business Overview
  94. 8.16.3 Ceva Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Ceva Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  96. 8.16.5 Ceva Recent Developments
  97. 8.17 CAVAC
  98. 8.17.1 CAVAC Company Information
  99. 8.17.2 CAVAC Business Overview
  100. 8.17.3 CAVAC Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 CAVAC Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  102. 8.17.5 CAVAC Recent Developments
  103. 8.18 Bioveta
  104. 8.18.1 Bioveta Company Information
  105. 8.18.2 Bioveta Business Overview
  106. 8.18.3 Bioveta Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Bioveta Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  108. 8.18.5 Bioveta Recent Developments
  109. 8.19 Agrovet
  110. 8.19.1 Agrovet Company Information
  111. 8.19.2 Agrovet Business Overview
  112. 8.19.3 Agrovet Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Agrovet Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Product Portfolio
  114. 8.19.5 Agrovet Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Value Chain Analysis
  2. 9.1.1 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Mode & Process
  6. 9.2 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Distributors
  9. 9.2.3 Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst